Company news

CSL Limited news in 2026

CSL Limited's news releases, calls and decks from 2026, newest first.

View company

Update - Notification of buy-back - CSL

November 1, 2026

Update - Notification of buy-back - CSL

October 29, 2026

CSL 2026 AGM Results of Meeting

October 26, 2026

CSL Limited Annual General Meeting 2026

October 26, 2026

Brian McNamee to retire Gordon Naylor appointed next Chair

October 25, 2026

CSL to Defend Class Action

October 21, 2026

CSL to Defend Class Action

October 21, 2026

CSL appoints Deborah Waterhouse as CEO & Managing Director

October 21, 2026

Appointment of New CEO

October 21, 2026

Appointment of New CEO

October 21, 2026

Update on U.S. Plasma Collection Network

October 8, 2026

CSL dan Alentis umum perkongsian global untuk membangunkan dan mengkomersialkan lixudebart bagi penyakit buah pinggang dan hati yang jarang berlaku

October 8, 2026

CSL prices US$1.5 billion in Corporate Bonds

October 6, 2026

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

October 4, 2026

CSL และ Alentis ประกาศความร่วมมือระดับโลก เพื่อพัฒนาและทำการตลาดยา lixudebart สำหรับโรคไตและตับที่พบได้ยาก

October 5, 2026

CSL enters exclusive agreement with Alentis Therapeutics

October 4, 2026

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

September 29, 2026

Update - Notification of buy-back - CSL

September 23, 2026

Update - Notification of buy-back - CSL

September 22, 2026

UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement

September 21, 2026

Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks

September 22, 2026

Update - Notification of buy-back - CSL

September 21, 2026

Update - Notification of buy-back - CSL

September 17, 2026

Update - Notification of buy-back - CSL

September 16, 2026

Notice of Meeting and Shareholder Pack 2026

September 16, 2026

Update - Notification of buy-back - CSL

September 15, 2026

Update - Notification of buy-back - CSL

September 14, 2026

Update - Dividend/Distribution - CSL

September 13, 2026

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

September 10, 2026

Update - Notification of buy-back - CSL

September 8, 2026

Application for quotation of securities - CSL

September 8, 2026

Notification regarding unquoted securities - CSL

September 8, 2026

Notification of cessation of securities - CSL

September 7, 2026

Notification of cessation of securities - CSL

September 3, 2026

Application for quotation of securities - CSL

September 3, 2026

Change in substantial holding

September 3, 2026

Appendix 3Y - Alison Watkins AM

September 3, 2026

Appendix 3Y - Elaine Sorg

September 3, 2026

Appendix 3Y - Costa Saroukos

September 3, 2026

Appendix 3Y - Cameron Price

September 3, 2026

Appendix 3Y - Samantha Lewis

September 3, 2026

Appendix 3Y - Carolyn Hewson AO

September 3, 2026

Appendix 3Y - Brian Daniels

September 3, 2026

Appendix 3Y - Andrew Cuthbertson AO

September 3, 2026

Appendix 3Y - Brian McNamee AO

September 3, 2026

Notification regarding unquoted securities - CSL

September 3, 2026

CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing

August 31, 2026

Agreements with U.S. on Drug Prices and Manufacturing

August 31, 2026

Appendix 3Y - Alison Watkins AM

August 27, 2026

Appendix 3Y - Costa Saroukos

August 27, 2026

Older news releases →

Calls in 2026

Decks in 2026